Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial
Sydney, Australia 28 July 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has commenced its 64/67Cu SAR-bisPSMA theranostic clinical trial in patients with metastatic castrate resistant prostate cancer (mCRPC) in the US. Patient recruitment has commenced with the opening of the…